The True Cost of an Infection: What the Numbers Don’t Fully Capture
A patient in the ICU develops a central line–associated bloodstream infection (CLABSI) on day 12 of admission. Clinically, the team responds quickly—blood cultures, broad-spectrum antibiotics, line removal, and supportive care. The infection is managed. But for the organization, the cost story is only beginning.
When healthcare leaders discuss CLABSI impact, the conversation often centers on the average estimated cost per case—frequently cited between $20,000 and $70,000 depending on patient acuity and setting. Yet this range only reflects a fraction of the true financial burden.
The direct costs are the most visible: additional ICU days, antimicrobial therapy, laboratory testing, imaging, and specialist consultations. These alone can quickly escalate depending on severity and complications such as septic shock or metastatic infection.
Less visible are the operational costs. A CLABSI often increases length of stay by 7–14 days or more, occupying high-value ICU or step-down capacity. That extended occupancy creates downstream effects—delayed admissions, postponed procedures, and reduced throughput across the system. In surgical or high-capacity environments, those delays translate directly into lost revenue opportunities.
Then there are labor and system costs. Infection control investigations, root cause analyses, reporting requirements, and prevention bundle reinforcement all require staff time—often pulling infection preventionists, nursing leadership, and quality teams away from proactive work.
Finally, there are financial penalties and quality-linked reimbursement impacts, particularly in value-based purchasing environments where CLABSI rates influence public reporting and payment adjustments.
A commonly overlooked dimension is the opportunity cost of prevention failure. Every CLABSI represents resources that could have been invested in prevention infrastructure, education, or other patient safety initiatives. When scaled across even a small number of infections annually, the cumulative financial impact can reach hundreds of thousands to millions of dollars per facility.
Evidence consistently shows that CLABSIs are among the most costly healthcare-associated infections in the United States, contributing significantly to preventable healthcare spending and avoidable patient harm. The key question for healthcare leaders is not simply what a CLABSI costs, but what it costs to allow one to occur. Because every HAI case is not just a clinical event, but also has a measurable and preventable financial impact.
Looking to reduce CLABSI rates and strengthen the financial performance of your infection prevention program? IPMA partners with organizations to improve central line maintenance practices, surveillance accuracy, and prevention strategy design that directly reduces infection-related cost burden.